Feasibility of using PALSAR technology as a signal amplifier for antibody bridging assay

The authors were employees of Sekisui Medical Co., Ltd. at the time of this study and may hold stock ownership in the company. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing assistance was utilized in the production of this manuscript. Writing assistance was funded by Sekisui Medical Co., Ltd.

留言 (0)

沒有登入
gif